BTAI · CIK 0001720893 · operating
BioXcel Therapeutics is a biopharmaceutical company that applies artificial intelligence to drug development, focusing on neuroscience and immuno-oncology. The company's commercial product, IGALMI, is a sublingual film approved for acute agitation associated with schizophrenia or bipolar I or II disorder in adults. The company is advancing several pipeline candidates in clinical development, including BXCL501, an orally dissolving dexmedetomidine film in Phase 3 trials for agitation-related conditions and substance use disorders; BXCL701, an oral innate immune activator for solid and liquid tumors that has completed Phase 1b/2a testing; and BXCL502, BXCL503, and BXCL504 for various neuropsychiatric and dementia-related indications.
BioXcel operates through its subsidiary, OnkosXcel Therapeutics LLC, which focuses on immuno-oncology development. The company maintains research collaborations with academic institutions including Columbia University, Yale University Medical School, and the University of North Carolina to support BXCL501 development.
The company operates at a relatively small scale with 37 full-time employees and is headquartered in New Haven, Connecticut. BioXcel was incorporated in Delaware in 2017 and is publicly traded on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-23.51 | $-23.51 | -282.3% | |
| 2023 | $-6.15 | $-6.15 | -3.9% | |
| 2022 | $-5.92 | $-5.92 | -46.2% | |
| 2021 | $-4.05 | $-4.05 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-28 | 0001558370-25-003985 | SEC ↗ |
| 2023-12-31 | 2024-03-22 | 0001558370-24-003784 | SEC ↗ |
| 2022-12-31 | 2023-03-16 | 0001558370-23-003940 | SEC ↗ |
| 2021-12-31 | 2022-03-11 | 0001558370-22-003335 | SEC ↗ |
| 2020-12-31 | 2021-03-12 | 0001558370-21-002916 | SEC ↗ |
| 2019-12-31 | 2020-03-09 | 0001558370-20-002196 | SEC ↗ |
| 2018-12-31 | 2019-03-12 | 0001558370-19-001798 | SEC ↗ |